Faisal Bukhari, MD
Internal Medicine · Sullivan, ILNPI 1376545509
Payments from drug & device makers
Across 348 payments — averaging $17.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sunovion Pharmaceuticals Inc.$580
- Astellas Pharma US Inc$541
- Johnson & Johnson$540
- Abbott$306
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$305
- Neurocrine Biosciences, Inc.$303
- plus $4K from 33 others
What the payments were for
- Speaking & faculty fees$561%
- Food & beverage$5,72493%
- Education$3826%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sunovion Pharmaceuticals Inc. | 33 | $580 |
| Astellas Pharma US Inc | 17 | $541 |
| Johnson & Johnson | 36 | $540 |
| Abbott | 16 | $306 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 23 | $305 |
| Neurocrine Biosciences, Inc. | 11 | $303 |
| Pfizer | 22 | $300 |
| AstraZeneca | 17 | $292 |
| Lilly USA, LLC | 17 | $286 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 17 | $261 |
| Amgen | 15 | $251 |
| Otsuka America Pharmaceutical, Inc. | 12 | $206 |
| Novartis | 10 | $194 |
| Biohaven Pharmaceuticals, Inc. | 13 | $190 |
| Biogen | 9 | $165 |
| Avanir Pharmaceuticals, Inc. | 10 | $161 |
| Amarin Pharma, Inc. | 10 | $156 |
| Novo Nordisk | 6 | $114 |
| Radius Health, Inc. | 5 | $102 |
| Xeris Pharmaceuticals, Inc. | 5 | $100 |
| Acorda Therapeutics, Inc | 4 | $76 |
| Merck | 6 | $75 |
| ERBE USA Inc | 1 | $75 |
| Teva Pharmaceuticals USA, Inc. | 3 | $59 |
| Bayer | 3 | $56 |
| Lundbeck LLC | 3 | $52 |
| Exact Sciences | 2 | $50 |
| Eisai Inc. | 3 | $47 |
| Organogenesis Inc. | 2 | $46 |
| UCB, Inc. | 3 | $42 |
| MDD US Operations, LLC | 3 | $39 |
| AbbVie(2 entities) | 2 | $38 |
| Phathom Pharmaceuticals, Inc. | 2 | $35 |
| Acadia Pharmaceuticals Inc | 2 | $32 |
| Kyowa Kirin, Inc. | 1 | $27 |
| Boehringer Ingelheim | 1 | $18 |
| Boston Scientific | 1 | $16 |
| Mylan Specialty L.p. | 1 | $14 |
| Vivus LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INGREZZA$121
How this compares
$6,162 in reported general payments places this provider in the 90th percentile of 5,182 internal medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 417 | $156,350 |
| OzempicSemaglutide | 104 | $105,314 |
| XareltoRivaroxaban | 242 | $89,485 |
| JardianceEmpagliflozin | 177 | $74,112 |
| JanuviaSitagliptin Phosphate | 105 | $58,684 |
| EntrestoSacubitril/Valsartan | 176 | $57,976 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 52 | $39,886 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 261 | $36,125 |
| MyrbetriqMirabegron | 94 | $35,879 |
| MounjaroTirzepatide | 24 | $30,534 |
| FarxigaDapagliflozin Propanediol | 53 | $29,245 |
| Divalproex Sodium | 278 | $29,068 |
| Breo ElliptaFluticasone/Vilanterol | 50 | $22,549 |
| TrulicityDulaglutide | 31 | $22,217 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 35 | $21,945 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $300 | $156,350417 claims |
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat, Spiriva Respimat | $18 | $124,744299 claims |
| Novo NordiskOzempic | $114 | $105,314104 claims |
| Johnson & JohnsonXarelto | $540 | $89,485242 claims |
| MerckJanuvia, Lagevrio (Eua) | $75 | $73,032119 claims |
| NovartisEntresto | $194 | $57,976176 claims |
| Lilly USA, LLCMounjaro, Trulicity | $286 | $52,75155 claims |
| AstraZenecaFarxiga, Brilinta | $292 | $36,97486 claims |
| Astellas Pharma US IncMyrbetriq | $541 | $35,87994 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $206 | $10,86317 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 5,182 internal medicine providers in Illinois.
Other internal medicine in Sullivan
- Dennis LevinsonChicago$25.3M
- Mary BrownRockford$16M
- Andrew BartlettChampaign$4.1M
- Danny SugimotoChicago$4M
- Peter O DonnellChicago$3.9M
- Daniel CatenacciChicago$3.5M
- Jeffrey GeohasEvanston$2.3M
- Patricia WalshChicago$2.1M
- Merle DiamondChicago$1.7M
- Yoko MomoyamaLombard$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.